Press Release

KPI Therapeutics to Give Corporate Update at Biotech Showcase Investor Conference during JP Morgan Week

CEO to highlight clinical progress on autoimmune platform

Download PDF

SEATTLE, Jan. 3, 2017 – KPI Therapeutics Inc., a clinical stage biotechnology company today announced it has been invited to give a corporate presentation at the Biotech Showcase Investor conference, Jan 10 at 8:15 am in San Francisco. KPI President and CEO Dr. Charles Magness will give a clinical update on its autoimmune drug platform. KPI’s lead drug dalazatide is Phase 2 ready and is in development for several systemic autoimmune diseases including lupus, arthritis and myositis, an orphan disease. Dr. Magness will also outline potential dermatology targets for research with the drug. Dalazatide is the first Kv1.3 channel blocker to be successfully brought into the clinic. KPI’s pipeline includes topical KPI-150 and eye drop KPI-190, also Kv1.3 channel blockers being developed for atopic dermatitis and dry eye syndrome/uveitis respectively.

About KPI Therapeutics

KPI Therapeutics is a clinical stage biotechnology company, which develops first in class therapies for unmet medical needs in autoimmunity. KPI leads an alliance of development partners under a common purpose to drive focused and efficient drug development. KPI partners include Kineta, Inc, Chimera Biotec, Life Chemicals, MPI Research, Medical Marketing Economics, CoMotion, the University Of Washington School Of Medicine and the Alliance for Children’s Therapeutics, which includes Seattle Children’s Research Institute. For more information about KPI please visit our website:

About dalazatide, KPI-150 and KPI-190

Dalazatide has completed a Phase 1b clinical trial in plaque psoriasis. It has a novel mechanism of action (MOA). Preclinical and clinical data have shown that dalazatide is a selective and potent blocker of the voltage-gated Kv1.3 potassium channel - a key channel in the activation of effector-memory T cells. Effector memory T cells are implicated in the pathology of many autoimmune diseases. Dalazatide was the first specific Kv1.3 inhibitor advanced into human clinical trials. Dalazatide is being studied as a potential therapy for multiple autoimmune diseases including myositis, lupus, ANCA Vasculitis, multiple sclerosis, psoriasis, psoriatic arthritis, rheumatoid arthritis, and inflammatory bowel diseases. Dalazatide is being developed jointly with Kineta Inc.

Topical KPI-150 and eye drop KPI-190 are also Kv1.3 inhibitors that are in development for atopic dermatitis (eczema) and eye diseases respectively. Atopic Dermatitis is a chronic inflammatory autoimmune disease, which results in itching, scratching, redness, scaling, insomnia and loss of skin surface. Uveitis and autoimmune dry eye syndrome are chronic life-long, inflammatory eye diseases, which can cause irreversible vision damage.

NOTICE: This document contains certain forward-looking statements, including without limitation statements regarding KPI’s plans for future research and development activities. You are cautioned that such forward-looking statements are not guarantees of future performance and involve risks and uncertainties inherent to KPI’s business which could significantly affect expected results, including without limitation progress of drug development, ability to raise capital to fund drug development, clinical testing and regulatory approval, developments in raw material and personnel costs, and legislative, fiscal, and other regulatory measures. All forward-looking statements are qualified in their entirety by this cautionary statement, and KPI undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

Contact Us